Verrica Pharmaceuticals Inc. (VRCA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US92511W2070
Verrica Pharmaceuticals Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 35.58 m USD |
| Operating income | -12.19 m USD |
| EBIT | -11.07 m USD |
| Net income | -17.89 m USD |
| Diluted EPS – continuing operations | -1.68 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
More stocks
- SLP Resources Bhd (7248.KL)
- Lifevantage Corp (LFVN)
- Nature Holdings Co. Ltd. (298540.KQ)
- Mirae Asset Daewoo Special Purpose Acquisition Company 4 Co. Ltd (333430.KQ)
- Jing-Jan Retail Business Co., Ltd. (2942.TWO)
- Great Elm Capital Corp. (GECC)
- ezCaretech Co. LTD (099750.KQ)
- Siamrajathanee Public Company Limited (SO.BK)
- Wentel Engineering Holdings Berhad (0298.KL)
- Huang Long Development Co Ltd (3512.TWO)
- CAG Group AB (publ) (CAG.ST)
- Feei Cherng Develop Technology Co., Ltd. (3313.TWO)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.